Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins. The founders, a married couple, ...

and less than 1% of Novo's sales come from inside the country where the company was founded in the 1920s. Novo Nordisk is ...

Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem ...

After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations, said that its net profit in the ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

Meanwhile, semaglutide remains on the shortages list, but Novo Nordisk hopes it won’t be for long. The company last week ...

Novo Nordisk (NVO) has released an update. Novo Nordisk, a leading global healthcare company, recently reported that its board members and ...

Investing.com -- Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its development pipeline.

Novo Nordisk ( (NVO) ) has released its Q3 earnings. Here is a breakdown of the information Novo Nordisk presented to its investors. Novo ...